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Abstract
Although genome-wide association studies have identified more than eighty genetic variants 
associated with non-small cell lung cancer (NSCLC) risk, biological mechanisms of these 
variants remain largely unknown. By integrating a large-scale genotype data of 15,581 lung 
adenocarcinoma (AD) cases, 8,350 squamous cell carcinoma (SqCC) cases, and 27,355 controls, 
as well as multiple transcriptome and epigenomic databases, we conducted histology-specific 
meta-analyses and functional annotations of both reported and novel susceptibility variants. 
We identified 3,064 credible risk variants for NSCLC, which were overrepresented in enhancer-
like and promoter-like histone modification peaks as well as DNase I hypersensitive sites. 
Transcription factor enrichment analysis revealed that USF1 was AD-specific while CREB1 
was SqCC-specific. Functional annotation and gene-based analysis implicated 894 target genes, 
including 274 specifics for AD and 123 for SqCC, which were overrepresented in somatic driver 
genes (ER=1.95, P=0.005). Pathway enrichment analysis and Gene-Set Enrichment Analysis 
revealed that AD genes were primarily involved in immune-related pathways, while SqCC genes 
were homologous recombination deficiency related. Our results illustrate the molecular basis of 
both well-studied and new susceptibility loci of NSCLC, providing not only novel insights into 
the genetic heterogeneity between AD and SqCC but also a set of plausible gene targets for 
post-GWAS functional experiments.
Keywords
Lung cancer; genome-wide association study; function annotation; immune; homologous 
recombination repair deficiency; genetic heterogeneity
Introduction
Lung cancer is the leading cause of cancer morbidity and mortality worldwide[1]. Non-
small cell lung cancer (NSCLC) is the main type of lung cancer, accounting for ~85% 
of all lung cancer cases[2]. Adenocarcinoma (AD) and squamous cell carcinoma (SqCC) 
represent the two major histological subtypes of NSCLC. Although tobacco smoking 
is generally considered as the major cause of lung cancer, genetic factors also play 
Qin et al. Page 3

















































an important role in the development of lung cancer. Genome-wide association studies 
(GWASs) have previously identified 81 lung cancer susceptibility variants in 51 loci that 
robustly associated with lung cancer risk[3, 4]; however, only a relatively small proportion 
of lung cancer heritability (0.7%~2.4%) can be explained by the variants identified so far[5, 
6]. Additionally, delineating the biological mechanism of susceptibility variants underlying 
the development of lung cancer has also lagged far behind[3].
The challenge of pinpointing predisposition genes in susceptibility loci lies in several 
aspects. First, most GWAS implicated variants are tag single-nucleotide polymorphisms 
(SNPs) which represent for all co-inherited SNPs in the same haplotype, and thus the direct 
inference of statistically associated SNPs rarely yields functional variants[7]. Second, as the 
vast majority (>80%) of the GWAS hits are located in the non-coding regions, distinguishing 
functional SNPs from non-functional ones can be a great challenge[8]. Third, as previous 
studies mainly focused on mixed NSCLC, the biological and genomic heterogeneity of lung 
AD and SqCC[9–11] also leads to a disparity of functional signals. Thus, further dissection 
of the genetic underpinnings of lung AD and SqCC is crucial for the understanding of lung 
cancer pathogenesis.
In recent years, the emergence of epigenomic datasets, such as the Encyclopedia of 
DNA Elements (ENCODE) project[12], the Functional Annotation of the Mammalian 
Genome (FANTOM) project[13], and the Roadmap Epigenomics project[14] provide a 
good opportunity to unveil the function of disease-associated signals from epigenomic 
level. By leveraging the wealth epigenomic data, many studies have attempted to illuminate 
the biological meanings of GWAS-implicated cancer risk loci. For example, a study from 
Michailidou et al.[15] examined the overlap of breast cancer variants with cis-regulatory 
elements (CREs) and observed a significant enrichment. Similar results were observed for 
the risk loci of colorectal, head and neck, ovary, and prostate cancers[16], and such CREs 
were active in disease-related cell lines[17]. Thus, incorporating functional information 
into association signals has the potential to improve our understanding of the biological 
consequences of human cancers.
In this study, we first conducted histology-specific genome-wide meta-analyses and then 
performed a comprehensive functional annotation of NSCLC susceptibility variants by 
integrating multiple in-house and publicly available databases. Our results first illustrate 
the molecular basis of all known susceptibility loci of lung cancer and provide novel insights 
into the genetic heterogeneity between lung AD and SqCC.
Materials and Methods
Study populations
We conducted a meta-analysis with 27,120 NSCLC cases (15,581 AD, 8,350 SqCC, and 
3,189 other cases) and 27,355 controls. Of all subjects, 26,655 Chinese participants were 
from our previously published Nanjing Medical University (NJMU) lung cancer GWAS 
study[4] and 27,820 European participants were from the TRICL-ILCCO OncoArray 
project[18]. NJMU lung cancer GWAS study was consist of three datasets, including 
19,546 participants (10,248 cases and 9,298 controls) from NJMU Global Screening Array 
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(GSA) project[4], 5,203 participants (2,126 cases and 3,077 controls) from NJMU GWAS 
project[19], and 1,906 participants (953 cases and 953 controls) from NJMU OncoArray 
project[4]. Informed consent was obtained from all the participants included in this study, 
and each study was approved by the corresponding institutional review board. Detailed 
demographic characteristics of included participants have been described in our previous 
study[4], and were provided in Table 1.
Quality control and imputation
Detailed imputation process has been described in our previous study[4]. Briefly, we 
first excluded samples with genotype completion rates <95%, gender discrepancies, 
familial relationships, extreme heterozygosity rates (6 S.D. from the mean), or population 
stratification (>6 S.D. from the mean on any one of the top ten principal components). 
Then, we excluded duplicate markers or SNPs with call rates <95%, minor allele frequencies 
(MAFs) <0.01 or Hardy-Weinberg equilibrium (HWE) P value <1×10−7 in controls or HWE 
P value <1×10−12 in cases. We phased the haplotypes with SHAPEIT v2[20] and imputed 
with IMPUTE2[21]. The 1000 Genomes Project (the Phase III integrated variant set release, 
across 2,504 samples) was set as the reference.
Identification of NSCLC risk loci
To perform functional annotation, we first conducted genome-wide meta-analyses for 
NSCLC, lung AD and SqCC respectively, and then derived a set of lung cancer risk 
associated index variants including both 81 previously reported SNPs (Table S1) and those 
with a genome-wide significant P value <1×10−6 in our overall NSCLC or histological meta-
analyses. For 81 previously reported variants, index variants were defined as those met either 
of the following criteria: (1) MAF ≥0.01; and (2) SNPs in weak linkage disequilibrium 
(LD, r2 <0.6) with each other. For other independent variants, index variants were defined 
if met one or more of the following criteria in our meta-analyses: (1) MAF ≥0.01; (2) with 
a genome-wide significant P value <1×10−6 in NSCLC, lung AD or SqCC meta-analysis; 
and (3) SNPs in weak LD with each other and previously reported variants (r2 <0.01). If one 
SNP identified in histology-specific meta-analysis also showed association with the other 
histology of lung cancer (AD or SqCC) (P <0.05), it was considered as NSCLC related. 
Thus, 67 index variants derived from both 81 previously reported SNPs and those from 
our genome-wide meta-analyses were included in the following analysis. Then, we further 
mining SNPs in strong LD (r2 ≥0.6) with above defined index SNPs and physically within 
500 kb upstream or downstream of the index SNP. All above defined index SNPs and 
associated SNPs in strong LD were considered as credible risk variants (CRVs) (Figure 1A).
Identification of target genes for NSCLC risk loci by functional annotation
To define candidate target genes for lung cancer risk loci, we performed functional 
annotation with an extended in silico prediction of GWAS targets (INQUISIT) strategy[15] 
and calculated a score for each gene-CRV pair representing for the coding impact or 
potential regulatory mechanisms (proximal or distal gene regulation) by integrating multiple 
lines of evidence (Table S2–3). Each target gene was scored based on distally regulation, 
proximally regulation, and coding sequence.
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For the distally regulated gene, one score was given if: (1) the CRV was located in an 
enhancer element that predicted to physically interact with the promoter of the target 
gene by FANTOM5[13] or PreSTIGE [22]; (2) the enhancer element containing the CRV 
overlapped with the transcription factor binding sites (TFBS) of one transcription factor (TF) 
(two scores were given if overlapped with more than one TF); (3) the CRV is an expression 
quantitative trait loci (eQTL) for that gene in the Genotype-Tissue Expression (GTEx), The 
Cancer Genome Atlas (TCGA) or Nanjing Lung Cancer Cohort (NJLCC) [23] databases; 
or (4) the gene was listed as a lung cancer somatic driver gene (except for driver gene 
enrichment analysis). Additionally, two scores were added if the CRV was also located in 
an enhancer element that physically interact with the promoter of that gene based on Hi-C 
experiment. However, the score was down-weighted by multiplying by 0.05 if the target 
gene was separated from the CRV by topologically associating domain (TAD) boundaries, 
or down-weighted by multiplying by 0.1 if the gene was low expressed in the GTEx normal 
lung tissues (less than 1% samples with Transcripts Per Million [TPM] greater than 0.1), 
TCGA tumor/adjacent samples (less than 1% samples with Fragments Per Kilobase Million 
[FPKM] greater than 0.1) and NJLCC tumor/adjacent samples (less than 1% samples with 
TPM greater than 0.1).
Proximally regulated genes were defined as those with CRVs located 1 kb upstream and 
100bp downstream surrounding the transcription start sites (TSSs). One score was given 
if: (1) the gene was overlapped with promoter histone modification peaks (H3K4me3 or 
H3K9ac); (2) the gene was listed as a lung cancer somatic driver gene (except for driver 
gene enrichment analysis); (3) the histone modification peak that the CRV resided was also 
intersected with the TFBS of TFs; or (4) the CRV is an eQTL for that gene in GTEx, TCGA 
or NJLCC databases. The down-weighted criteria were the same as that for distally regulated 
genes.
CRVs located in the exonic regions were evaluated for their impact on the protein function. 
Combined Annotation Dependent Depletion (CADD)[24], Functional Analysis through 
Hidden Markov Models (FATHMM)[25], LRT[26], MutationTaster[27], PolyPhen-2[28], 
and Sorting Tolerant from Intolerant (SIFT)[29] were used for the evaluation of missense 
variants. Other scoring strategy was the same as that for distally regulated genes.
Altogether, scores in the distal regulation category range from 0 to 7, in the promoter 
category from 0 to 4, and in the coding category from 0 to 3. We classified the candidate 
target genes into four levels based on the integrated scores: level 1 (distal score ≥4, promoter 
score ≥3, or coding score =3), level 2 (distal score 1–3, promoter score 1–2, or coding score 
1–2), level 3 (any score greater than 0), and level 4 (score 0). Genes categorized into level 
1–2 were considered as potential targets and were included in the following analysis.
Expression quantitative trait loci analysis based on NJLCC and TCGA data
In addition to the GTEx project (v7), we also performed eQTL analysis with data from 
NJLCC and TCGA projects. The NJLCC[23] project included 90 Chinese NSCLC samples 
with available clinical information, gene expression data, copy number variation profiles 
and matched genotyping data. Gene expression data was available for 98 tumor/adjacent 
pairs. NJLCC samples were genotyped with whole-genome sequencing and the expression 
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data was quantified by RNA-seq (Illumina HiSeq 1500 platform)[23]. A systematic quality 
control (QC) procedure was performed to filter out samples with missing genotypes and 
duplicates. Principal component analysis (PCA) was also performed. Finally, all 90 NJLCC 
samples (55 lung ADs and 35 SqCCs) were included in the eQTL analysis.
Similarly, the TCGA project included 106 NSCLC samples with matched clinical 
information, gene expression data, copy number variation data, and genotyping data. TCGA 
samples were genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 and the 
data was downloaded from the TCGA Firehose at the MIT Broad Institute. The RNA-seq 
(Illumina) based expression data of 106 TCGA matched adjacent normal samples was 
quantified by FPKM and obtained from the UCSC Xena website. For the genotyping data, 
we also performed a systematic QC procedure and PCA, and 3 TCGA samples with Asian 
ancestry were removed. As a result, 103 TCGA samples (55 lung ADs and 48 SqCCs) 
remained in the following analysis.
For eQTL analysis, we performed a linear regression using the R package Matrix eQTL[30] 
with default parameters. We set gene expression as the outcome, and SNP genotype as the 
covariate of interest with adjustment for age, gender, smoking status, the top ten principal 
components, and somatic copy number status.
Functional enrichment analysis of defined CRVs
To investigate the enrichment or depletion in chromatin modification peaks, we estimated 
the distribution of above CRVs in active promoter and enhancer regions identified in normal 
lung tissues, lung fibroblasts (NHLF), and lung cancer (A549) cell lines by using Variant Set 
Enrichment (VSE)[31]. The same analysis was performed in three lung fibroblasts (IMR90, 
HPF and AG04450) and A549 cell lines to evaluate the overrepresentation of CRVs in 
DNase I hypersensitive sites (DHS) regions or TFBS. All the histone modification peaks of 
promoter and enhancer marks (H3K4me3, H3K9ac, H3K4me1 and K3K27ac), DHS, and 
TFBS data were downloaded from the UCSC Genome Browser.
Gene-based analysis
We performed gene-based analysis with genome-wide gene-based association study 
(GWGAS) in MAGMA[32]. The P values from the GWAS meta-analyses for lung cancer, 
lung AD and SqCC were used as input, and all 19,427 protein-coding genes from the 
NCBI 37.3 gene definitions were used as the basis for GWGAS. We annotated all SNPs 
in our genome-wide meta-analyses to above genes, resulting in 18,233, 18,233 and 18,232 
protein-coding genes that were represented by at least one SNP in the NSCLC, lung AD or 
SqCC meta-analyses, respectively. Genes with Benjamini-Hochberg (BH) adjusted P value 
<0.05 were considered as significant.
Driver gene enrichment analysis
A gene was considered as lung cancer somatic driver gene if met one of the following 
criteria: (1) the gene was included in the COSMIC Cancer Gene Census (v78) and showed 
evidence to be lung cancer related[33]; (2) the gene was categorized as lung cancer-related 
mutational drivers, somatic copy number alteration (SCNA) drivers, or fusion drivers in 
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the IntOGen database[34]; or (3) the gene was identified as significantly mutated genes 
or SCNA-related genes in recent whole-genome or whole-exome sequencing studies[23, 
35–39]. Finally, we listed a total 374 coding genes and 4 non-coding genes as lung cancer 
somatic driver genes. To evaluate the enrichment of these genes in our defined lung cancer 
target genes, we first re-scored genes implicated by INQUISIT, and then examined the 
overlap between this list of drivers and the target genes with different levels of evidence and 
performed fisher exact test to obtain the significance. To avoid the bias of non-coding genes, 
only protein-coding genes were included in this analysis.
Pathway enrichment analysis
We performed pathway enrichment analysis on the above defined candidate target genes 
as well as genes identified by gene-based analysis to evaluate their potential function in 
the development of lung cancer. The analysis was conducted with the Reactome Pathway 
Database[40] using R package clusterProfiler[41] and pathways with BH adjusted P value 
<0.05 were retained.
Gene-Set Enrichment Analysis (GSEA)
The immune infiltration proportions[42] and homologous recombination deficiency (HRD)
[43] index of TCGA lung AD and lung SqCC samples were downloaded from previously 
published studies. We first calculated the correlation coefficients between the proportions 
of six types of immune cells (B cell, CD4 T cell, CD8 T cell, Neutrophils, Macrophages 
and Dendritic cells) or HRD index and the expression of all protein-coding genes. Then, 
a ranked list of correlation coefficient was analyzed by Gene-Set Enrichment Analysis 
(GSEA) with our predefined lung AD and SqCC genes. This analysis was performed with R 
package clusterProfiler[41].
Statistical analyses
Detailed description for the meta-analysis of GWAS data from Chinese and European 
populations was provided in our previous study[4]. Briefly, the association testing for each 
variant was performed using the SNPTEST software (v2.5.4) with adjustment for age, 
gender, and the principal components. Meta-analysis was performed with the fixed-effects 
inverse variance-weighting approach by using METAL [44]. Genetic variant with I2 ≥75% 
or P value for Cochran’s Q statistic ≤1.0×10−4 was considered with a high degree of 
heterogeneity, and was excluded from further analysis [45, 46]. The LD coefficients (R2 
and D’) was calculated with PriorityPruner, and the genotyping data of the East Asian 
and European populations from the 1000 Genomes Project (the Phase III integrated variant 
set release) were set as the reference. General analyses were performed with R software 
(version 3.5.1). All statistical tests were two-sided.
Results
Definition of credible risk variants for non-small cell lung cancer
We performed overall and histological GWAS meta-analyses (Figure 1A, Table 1). In 
order to clarify potential functional signals, we first defined 67 index SNPs based on the 
following criteria: (1) 58 index SNPs represented for 81 previously reported SNPs (r2 ≥ 
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0.6) (Table S1); and (2) 9 independent index SNPs with a meta P value <1×10−6 in our 
overall NSCLC or histological meta-analyses (Table S4). Of 9 SNPs with a meta P value 
<1×10−6, two were located in previously reported loci but showed weak LD (r2 <0.01) with 
previously reported SNPs (6p22.1: rs1815741: OR=0.86, 95% CI=0.81–0.91, P=2.99×10−7; 
11q23.3: rs4938515: OR=1.07, 95% CI=1.04–1.10, P=3.46×10−7), and the other seven SNPs 
included five for NSCLC (4p14: rs116205103: OR=0.83, 95% CI=0.77–0.89, P=1.82×10−7; 
15q24.1: rs76354137: OR=0.92, 95% CI=0.88–0.95, P=5.74×10−7; 2q21.3: rs3217451: 
OR=0.90, 95% CI=0.87–0.94, P=7.35×10−7; 4q27: rs35661893: OR=0.93, 95% CI=0.91–
0.96, P=3.56×10−6; 13q24: rs719739: OR=0.94, 95% CI=0.92–0.97, P=1.94×10−5), one for 
AD (9q31.3: rs12006500: OR=1.12, 95% CI=1.07–1.16, P=8.43×10−8), and one for SqCC 
(8p23.1: rs2945908: OR=0.89, 95% CI=0.85–0.93, P=7.92×10−7) (Table S4, Figure S1).
Then, we defined additional CRVs for further functional annotation (SNPs with r2 ≥ 0.6 
with one of 67 independent index SNPs and within 500kb upstream or downstream of the 
corresponding index SNPs). Finally, we identified 3,064 CRVs in the following analysis, 
including 1,842 for NSCLC, 1,020 for AD and 220 for SqCC (Figure 1A).
Enrichment analysis of NSCLC CRVs
Most of the defined CRVs were in the intronic (intronic and ncRNA intronic: 1489; 
48.60%) or intergenic regions (intergenic, downstream and upstream: 1444; 47.13%) (Figure 
1B). We systematically evaluated the enrichment of these variants in histone modification 
peaks. Interestingly, we observed a significant enrichment of NSCLC related CRVs in 
promoter-like (H3K4me3 and H3K9ac) and enhancer-like (H3K4me1 and H3K27ac) histone 
modification peaks in normal lung tissues, lung fibroblasts (NHLF) and lung cancer (A549) 
cell lines (Figure 1C), and most (7/11) of the enrichment degrees were greater for lung 
AD related CRVs (Figure 1C). Additionally, the defined CRVs were also enriched in DHS 
regions in lung fibroblasts (AG04450) and lung cancer (A549) cell lines (Figure 1C).
Then, we conducted TF enrichment analysis and strong signals were observed for the 
binding sites of ATF3, POLR2A, TCF12, MAX, YY1, CTCF, and MAFK in lung fibroblasts 
(IMR90 and AG04450) and lung cancer (A549) cell lines at the significant level of PBH 
<0.05. Of these TFs, CTCF (HPF, AG04450 and IMR90), RAD21 (IMR90) and USF1 
(A549) were special for lung AD while TCF12 (A549) and CREB1 (A549) were for lung 
SqCC (Figure 1D).
Additionally, 22 of the 39 exonic variants were non-synonymous, including two nonsense 
and 20 missense variants (Table S5, Figure 1B). The index SNP rs11571833 (K3326*, 
c.A9976T) in 13q13.1 was a nonsense variant in exon 27 of BRCA2. The T allele could 
significantly increase the risk of lung cancer (OR=1.50, 95% CI=1.26–1.78, P=4.63×10−6). 
Of the missense variants, rs17121881 (c.T281A, I94N) in AMICA1 was predicted with 
the highest CADD score (CADD score=23.5) and could lead to an isoleucine-to-asparagine 
change. Rs17121881 was in exon 3 of AMICA1 and showed strong LD with the index 
SNP rs55768116 (r2=0.78) in 11q23.3. The A allele of rs17121881 could significantly 
increase the risk of lung cancer (OR=1.08, 95% CI=1.05–1.11, P=2.10×10−9) as well as 
reduce the expression of AMICA1 (GTEx: β=−0.10, P=0.005; NJLCC: β=−0.18, P=0.02). 
Interestingly, AMICA1 also showed a decreased expression in both lung AD and SqCC 
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samples when compared to adjacent normal samples in TCGA (AD: P=1.03×10−17; SqCC: 
P=7.75×10−23) and NJLCC (AD: P=1.76×10−18; SqCC: P=6.58×10−18) data (Figure S2), 
suggesting a tumor suppressor role during the development of lung cancer.
Systematic functional annotation of NSCLC CRVs
To link the candidate variants to genes, we then applied an extended INQUISIT functional 
annotation strategy and mapped CRVs to potential target genes by evaluating the impact on 
coding sequences, proximal promoter, and distal enhancer regulations (Figure 1A). Among 
all 3,064 CRVs, the coding impact evaluation strategy aligned CRVs to 25 genes, the 
proximal regulatory gene mapping strategy matched CRVs to 624 genes, and the distal 
regulatory gene mapping strategy annotated CRVs to 1,014 genes (Table S6). Above 
findings resulted in 1,047 unique mapped genes, among which 803 genes categorized as 
level 1 and 2 were considered as functional target genes and included in the following 
analysis (distal regulation strategy: 589 genes; proximal regulation strategy: 604 genes; 
coding impact strategy: 18 genes) (Figure 2A). Of these 803 genes, 395 were implicated by 
at least two mapping strategies, and 13 were implicated by all three (Figure 2B, Table S6). 
Additionally, 227 genes were implicated in lung AD samples while only 82 genes were in 
lung SqCC samples.
Of the newly identified genes, CASP8 was in a locus defined in our previous study[4] 
and was implicated by all three mapping strategies. The index SNP rs3769821 at 2q33.1, 
located in the histone modification marks targeting both promoters and enhancers in A549 
and NHLF cell types (Figure 2C–D), was confirmed as a cis-eQTL variant for CASP8 
in 383 GTEx lung tissues (P=1.09×10−37) (Figure 2E). Interestingly, we also identified a 
missense variant (rs3769823, c.41A>G, p.Lys14Arg), in strong LD (r2=1) with rs3769821, 
that was located in the first exon of CASP8 isoform 7 (Figure 2D). This isoform was 
highly expressed in normal lung tissues and was found to be regulated by rs3769823 
(P=2.39×10−10) (Figure 2F). Additionally, we identified RAD52 as a lung SqCC related 
gene which was regulated by both distal and proximal elements (Figure S3). Rs11571376 
(12p13.33) was located at the promoter region of RAD52 and the C allele could significantly 
increase the risk of lung cancer (OR=1.10, 95% CI=1.05–1.14, P=2.27×10−5). Interestingly, 
C allele of rs11571376 was also associated with the expression of RAD52 in normal lung 
tissues (beta=0.21, P=2.30×10−17), and the expression of RAD52 was significantly elevated 
in lung SqCC samples (TCGA: P=1.71×10−4; NJLCC: P=6.27×10−5) (Figure S3). For lung 
AD, we also identified a novel gene LIME1 with the highest INQUISIT score. Rs6122147, 
in strong LD with the index SNP rs41309931 (r2=0.98) in 20q13.3, was located in a distal 
enhancer element that physically interacted with the promoter of LIME1 in A549 cell line 
(Figure S4A). The T allele of rs6122147 could significantly increase the risk of lung cancer 
(OR=1.06, 95% CI=1.02–1.11, P=4.42×10−3) and decrease the expression of LIME1 in 
normal lung tissues (β=−0.14, P=4.20×10−4) (Figure S4B).
Gene-based analysis and driver gene enrichment analysis
To estimate the aggregated association of lung cancer, we performed GWGAS analysis 
using MAGMA and identified 154 lung cancer associated genes (Figure 3A, Table S7–
9), of which 62 have been implicated in previous functional annotation analysis (Figure 
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2A). Of these 154 genes, 70 genes were specific for AD and 57 were specific for SqCC. 
When combined with 803 genes identified by INQUISIT, we implicated a total of 894 
susceptibility genes for lung cancer (Figure 2A), of which 274 were specific for AD and 123 
were for SqCC (Figure 3B).
Then, we evaluated the association between our defined target genes and previously known 
somatic driver genes (Table S10). To avoid the bias of non-coding genes, only protein-
coding genes were included in this analysis. Among the genes implicated by INQUISIT 
(level 1–4), we observed an enrichment of our defined target genes in 374 established 
lung cancer somatic-driver genes (23 out of 374 genes, ER=1.95, P=0.005), including 
EGFR, CDKN2A, CHEK2, and TP53BP1. The enrichment degree increased with the 
level of evidence (level 1: ER=14.05, P=6.90×10−5; level 2: ER=1.38, P=0.30; level 3: 
ER=2.22, P=0.06; level 4: ER=0.00, P=1.00; Ptrend=0.06). Similar results were found when 
genes implicated by distal regulation (ER=1.97, P=0.005; Ptrend=0.95), proximal regulation 
(ER=1.43, P=0.25; Ptrend=2.95×10
−8), and coding impact (ER=4.64, P=0.08; Ptrend=0.13) 
were included. For genes derived from gene-based analysis, we also observed a significant 
enrichment in lung cancer somatic-driver genes (ER=4.48, P=3.87×10−5). Additionally, four 
somatic drivers (PTK6, CBL, MECOM, and SVEP1) were implicated specially for lung AD 
(ER=2.48, P=0.09), but no lung SqCC somatic drivers were detected.
Pathway enrichment analysis
To further explore biological pathways involved in the process of lung tumorigenesis, we 
performed pathway enrichment analysis of our defined target genes. To avoid the influence 
of non-coding genes, we only included 592 protein-coding genes in this analysis. The 
result revealed the involvement of 29 pathways (PBH<0.05) in the development of NSCLC, 
including 20 pathways related to immune function, such as PD-1 signaling (P=1.09×10−13) 
and interferon gamma signaling pathway (P=1.15×10−10), and six pathways in the neuronal 
system that related to nicotinic acetylcholine receptors, and three pathways in the DNA 
repair system (Figure 3C, Table S11). We also performed the same analysis for lung AD 
and SqCC genes, and identified that lung AD related genes were specifically enriched in 
immune related pathways (Figure 3D, Table S12), while lung SqCC genes were enriched in 
homologous recombination (HR)-related repair pathways (Figure 3E, Table S13), suggesting 
diverse mechanisms underlying the development of lung AD and SqCC.
Above findings indicated the importance of immune function and HR repair in the 
carcinogenesis of lung cancer. Thus, we evaluated the association of defined lung cancer 
genes with immune infiltration proportions and HRD index in TCGA lung AD and SqCC 
samples. Interestingly, we identified that lung SqCC genes were overrepresented in HRD-
related genes (NES=1.33, P=0.05) (Figure 3F) while lung AD genes were significantly 
overrepresented in four types of immune cells-related genes (B cell: NES=1.39, P=0.002; 
CD4 T cell: NES=1.32, P=0.01; CD8 T cell: NES=1.31, P=0.04; Neutrophil: NES=1.19, 
P=0.10; Macrophage: NES=1.02, P=0.44; Dendritic: NES=1.46, P=0.002) while lung SqCC 
genes not (B cell: NES=1.22, P=0.15; CD4 T cell: NES=1.14, P=0.26; CD8 T cell: 
NES=−1.06, P=0.29; Neutrophil: NES=0.94, P=0.62; Macrophage: NES=−1.22, P=0.17; 
Dendritic: NES=1.00, P=0.50) (Figure 3G–J).
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In this study, we performed a combined strategy of large-scale genome-wide meta-analysis 
and functional annotation to identify biological significance of lung cancer susceptibility 
loci and implicated a total of 894 candidate target genes. These predisposition genes 
could modify the risk of lung cancer by both shared and histology-specific transcriptional 
(enhancers, promoters and TF) or translational (missense and nonsense variants) regulations. 
Furthermore, pathway enrichment and GSEA analysis indicated the importance of immune 
and HR-related DNA repair during the carcinogenesis process of lung AD and SqCC. These 
findings provided both a rich set of plausible gene targets for further functional studies and 
novel insights into understanding the biological underpinnings underlying the development 
of different histology types of lung cancer.
Consistent with previous studies, NSCLC CRVs were primarily mapped to the non-coding 
regions and showed a strong enrichment in CREs such as enhancer elements and histone 
modification peaks, suggesting that these variants contributed to the development of 
NSCLC mainly through transcriptional regulation. Interestingly, TFBS enrichment analysis 
implicated some pathology-specific TFs. CREB1 (cyclic AMP response element-binding 
protein) is a transcriptional coactivator which plays important roles in the differentiation 
of bronchial epithelial cells and is overexpressed in NSCLC samples[47]. Many studies 
have identified that CREB1 could be activated by nicotine exposure[48, 49], and the 
activated CREB1 recruits additional transcriptional machinery elements and leads to 
tumorigenesis[49]. Thus, CREB1 could be a possible target for the pathobiological process 
of smoking induced lung SqCC. As a member of the basic helix-loop-helix leucine zipper 
family, USF1 (upstream transcription factor 1) functions as a cellular transcription factor[50] 
and regulates the expression of SP-A[51]. SP-A is a lung-specific gene, especially for type 
II cells which is the origin of lung AD[51]. Thus, USF1 may regulate the risk of lung AD 
by modifying the expression of SP-A. Although exact roles of these TFs in the susceptibility 
to lung cancer have not been comprehensively studied, the overrepresented binding sites 
provides an improved understanding of the transcriptional regulation mechanism in NSCLC 
etiology.
In previous studies, the development of lung AD and SqCC were found to share many 
genetic factors[3, 4]. However, in recent years, accumulating evidence suggested that these 
two types of lung cancer also had large discrepancy in terms of both germline variations 
and somatic alterations[18]. In this study, we identified a set of predisposition genes both 
shared by lung AD and SqCC and specific to each histology. One of the most interesting 
result is the identification of CASP8 in 2q33.1, a NSCLC risk locus reported in our previous 
study[4]. CASP8 encodes caspase 8, which is a multivalent controller of innate immune 
signaling and inhibits inflammasome activation in dendritic cells, interferon-regulatory 
factor 3 activation and pro-inflammatory cell death[52]. CASP8 has been implicated as 
a susceptibility gene for multiple cancers except for lung cancer[53, 54]. In this study, 
we identified that the expression of CASP8 is regulated by both a cis-eQTL in the 
enhancer element and a missense variant in the major isoform, suggesting a potential 
joint modification mechanism by which the susceptibility variants affect NSCLC risk[55]. 
Additionally, we identified some pathologically specific genes, such as LIME1 for AD and 
Qin et al. Page 12

















































RAD52 for SqCC. LIME1 encodes a membrane raft-associated adaptor protein which is 
an organizer of immunoreceptor signaling[56] and involves in CD4 and CD8 coreceptor 
signaling[57]. Thus, we speculate that LIME1 might regulate lung AD risk by modifying 
immune response. RAD52 is a key member in HR repair[58], which functions in DNA 
repair during S phase of the cell cycle[59] and act as a regulator of genomic stability[60]. In 
this study, we identified that RAD52 expression was elevated by cis-eQTLs in both proximal 
and distal regulatory elements in lung SqCC samples, suggesting a tumor-promoting role 
of RAD52 in the development of lung SqCC[61]. Above results indicate an important role 
of immune response during lung AD carcinogenesis as well as HR deficiency during lung 
SqCC carcinogenesis.
Interestingly, pathway enrichment and GSEA analysis also provided evidence for the 
importance of immune system and HR-related DNA repair during the development of lung 
AD and SqCC. Tumor-prompting inflammation is defined as a tumor-enabling hallmark 
of cancer[62] and has previously been implicated in lung cancer[63, 64]. Our recent work 
also provided evidence for the specific association of immune infiltration with lung AD, 
and identified that inflammatory microenvironments formed in the early stage of lung 
AD[23], suggesting that immune infiltration occurring in the initial stage is the major risk 
factor for lung AD. As an indication of genomic instability[65], elevated somatic HRD 
level has also been reported in lung SqCC[43]. The strong association between lung SqCC 
susceptibility genes and HRD observed in this study provided additional evidence that the 
somatic differences may have genetic ancestry origins and could regulate lung SqCC risk. 
As cigarette smoking is the major causal factor for lung SqCC[66], we propose that the 
continuous exposure to tobacco may directly lead to an increased level of HRD[66], and 
finally lead to lung SqCC. Thus, the use of PD1/PD-L1 and PARP inhibitors, which target 
immune infiltration and HRD[67, 68], implicate significant potential for the prevention of 
lung AD and SqCC.
However, the interpretation of our findings needs to be considered within the limitations of 
the study. First, the aggregation of susceptibility variants identified in both European and 
Chinese populations prevented us from capturing the genetic heterogeneity within different 
ethnic and individuals. Second, as the annotation data used in this study were obtained 
from different sources of tissues and cell types, further biological experiments are needed to 
elucidate the exact molecular mechanisms of these variants underlying the development of 
lung cancer.
In conclusion, by integrating GWAS information, in-house and publicly available biological 
data, we illustrate the molecular basis of both well-studied and newly identified lung 
cancer susceptibility loci and provide novel insights into the understanding of genetic 
heterogeneity between lung AD and SqCC, which may serve as guides for post-GWAS 
functional experiments and clinical drug target testing.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations:
NSCLC non-small cell lung cancer
AD adenocarcinoma
SqCC squamous cell carcinoma
GWAS genome-wide association study
SNP single-nucleotide polymorphism
ENCODE Encyclopedia of DNA Elements
FANTOM Functional Annotation of the Mammalian Genome
CRE cis-regulatory element
NJMU Nanjing Medical University
GSA Global Screening Array
MAF minor allele frequency
HWE Hardy-Weinberg equilibrium
LD linkage disequilibrium
CRV credible risk variant
TFBS transcriptional factor binding sites
TF transcription factor
eQTL expression quantitative trait loci
GTEx Genotype-Tissue Expression
TCGA The Cancer Genome Atlas
NJLCC Nanjing Lung Cancer Cohort
TAD topologically associating domain
TPM Transcripts Per Million
FPKM Fragments Per Kilobase Million
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TSS transcription start site
CADD Combined Annotation Dependent Depletion
FATHMM Functional Analysis through Hidden Markov Models
SIFT Sorting Tolerant from Intolerant
QC quality control
PCA principal component analysis
NHLF lung fibroblasts
VSE Variant Set Enrichment
DHS DNase I hypersensitive sites
GWGAS genome-wide gene-based association study
BH Benjamini-Hochberg
SCNA somatic copy number alteration
HRD homologous recombination deficiency
GSEA Gene-Set Enrichment Analysis
HR homologous recombination
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Figure 1. Functional evaluation of 3,064 lung cancer related credible risk variants (CRVs) 
defined in this study.
A. Flowchart for the study design.
B. Genomic distribution of 3,064 lung cancer CRVs.
The x-axis indicates the number of CRVs included in the genomic region type.
C. Enrichment of defined lung cancer CRVs (1,020 for lung AD and 220 for SqCC) in 
histone modification peaks and DNase I hypersensitive sites.
The x-axis indicates different types of modification peaks in lung cancer cell line types. 
A549, lung AD cell line; NHLF, lung fibroblasts cell line; AG04450 and HPF, lung 
fibroblasts cell lines; Lung, normal lung tissue.
D. Enrichment of defined lung cancer CRVs (1,020 for lung AD and 220 for SqCC) in 
transcriptional factor binding sites.
The x-axis indicates binding sites of different transcriptional factors. IMR90, lung 
fibroblasts cell line.
Qin et al. Page 24

















































Figure 2. Implicated lung cancer target genes by functional annotation.
A. Circos plot showing 803 implicated genes by distal mapping, promoter mapping and 
coding mapping strategies.
Blue indicates the mapping strategy (from inside to outside: distal, promoter, and coding 
mapping) and red indicates if the implicated gene is a driver gene.
B. Venn diagram showing the number of overlapped genes implicated by distal mapping, 
promoter mapping, coding mapping strategies, and GWGAS.
C. Detailed functional annotation results for three risk loci of lung cancer.
The x-axis indicates the implicated genes, and y-axis indicates the annotation evidence 
types.
D. Genomic region of CASP8 in 2q33.1.
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E-F. eQTL analysis of two CRVs (rs3769821 and rs3769823) and CASP8 expression in 383 
GTEx lung tissues.
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Figure 3. Implicated lung cancer target genes by gene-based and pathway enrichment analyses.
A. Manhattan plot of the GWGAS analysis for NSCLC meta-analysis.
The y axis shows the −log10 transformed two-tailed P value of each gene from a linear 
model, and chromosomal position is shown on the x axis.
B. Venn diagram showing the overlap of genes implicated by INQUISIT and MAGMA in 
NSCLC, lung AD and SqCC.
C. Pathway enrichment analysis of all genes implicated by INQUISIT and GMAMA for 
NSCLC.
D. Pathway enrichment analysis of lung AD genes.
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E. Pathway enrichment analysis of lung SqCC genes.
F. GSEA analysis of NSCLC, lung AD and SqCC genes with homologous recombination 
deficiency.
G. GSEA analysis of NSCLC, lung AD and SqCC genes with B cell proportion.
H. GSEA analysis of NSCLC, lung AD and SqCC genes with CD4 T cell proportion.
I. GSEA analysis of NSCLC, lung AD and SqCC genes with CD8 T cell proportion.
J. GSEA analysis of NSCLC, lung AD and SqCC genes with dendritic cell proportion.
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Demographic characteristics of lung AD, SqCC and non-cancer controls included in this study
NJMU project TRICL-ILCCO OncoArray project
Lung AD Lung SqCC Control Lung AD Lung SqCC Control
Number % Number % Number % Number % Number % Number %
Total 8762 100.0 3860 100.0 13328 100.0 6819 100.0 4490 100.0 14027 100.0
Age (Mean±S.D.) 58.63±10.52 61.16±9.42 59.31±10.42 63.57±10.80 64.84±9.62 61.77±10.29
Gender
Male 4650 53.1 3470 89.9 8605 64.6 3626 53.2 3489 77.7 8638 61.6
Female 4112 46.9 390 10.1 4723 35.4 3192 46.8 1001 22.3 5386 38.4
Missing value n/a n/a n/a n/a n/a n/a 1 0.0 n/a n/a 3 0.0
Smoking status
Ever smoker 3364 38.4 3172 82.2 5606 42.1 5771 84.6 4276 95.2 9339 66.6
Life-long non-smoker 5397 61.6 688 17.8 7720 57.9 974 14.3 156 3.5 4412 31.5
Missing value 1 0.0 n/a n/a 2 0.0 74 1.1 58 1.3 276 1.9
Abbreviations: AD, adenocarcinoma; SqCC, squamous cell carcinoma.
n/a: No patients with missing information.
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